00:01The share price of pharmaceutical company AstraZeneca rose in European trading on Monday after the company reconfirmed its full-year
00:10outlook following second-quarter results that beat analysts' expectations.
00:15Net profit climbed more than 2% to 2.2 billion euros in three months to the end of June,
00:22compared with the same period last year, driven by continued strong growth in sales of its cancer and rare disease
00:29medicines.
00:31Alongside its blockbuster medicines, AstraZeneca is investing in treatment for opacity.
00:37Results released in June showed that patients taking the highest dose of AstraZeneca's experimental weight-loss pill, Elegoglipron, lost an
00:46average of 10.5% of their body weight after 26 weeks, with weight loss reaching 11.8% after
00:5436 weeks.
00:55If confirmed in further trials, the treatment could mark AstraZeneca's entry into the highly lucrative weight-loss drug market, currently
01:04dominated by Denmark's NovoNoDisc and US-based Eli Lilly.
Comments